The global pet cancer therapeutics Market is projected worth US$345.2 million by 2026 and the market is projected to showcase 10.6% CAGR during the forecast period. The pet cancer therapeutics market is driven by the rapid adoption of innovative pet care medicines.
The growing trend of pet adoption such as dogs and cats owing to theenhanced economic status of people will drive the global market. Furthermore, the rising prevalence of pet cancer and growing pet healthcare expenditure will stimulate the growth of the global pet cancer therapeutics market. Growing research and development initiatives by manufacturers to treat pet cancer will result in the launch of novel products in the market over the forecast years. The key players with a strong product portfolio are expected to expand the market share with their innovative treatments. The contrary effects of pet cancer drugs and lack of awareness about pet diseases among the pet owners will restrain market growth. The cost of pet cancer therapeutics will further hamper the pet health in most developing countries across the globe.
The mast cell cancer sub-segment is expected to hold the largest share of the global pet cancer therapeutics market. Also, the availability of various drugs for cancer treatment. But, the shifting trend from the mast cell cancer to other cancer treatments is expected to grow at a moderate pace during the forecast period.The dog cancer therapeutics market in the species segment held the largest revenue in the global market in the upcoming years.The rise in the existence of the high number of marketed drugs and vaccines for cancer treatment in dogs will boost the overall market growth.
The global pet cancer therapeutics market is segmented into medicine type, species, cancer type, and region. On the basis of medicine type, the global pet cancer therapeutics market is segmented into vaccines and chemotherapy drugs. On the basis of species, the global pet cancer therapeutics market is segmented into dogs and cats. On the basis of cancer type, the global pet cancer therapeutics market is segmented into melanoma, mammary, squamous cell cancer, mast cell cancer, mammary, and lymphoma. On the basis of the region, the global pet cancer therapeutics market is segmented into North America, Latin America, Europe, Asia Pacific, and Middle East & Africa.
Based on the type, the global pet cancer therapeutics market can majorly be segmented into three sub-segments, which are water-based, solvent-based, and UV-cured. The UV-cured sub-segment is expected to dominate the global pet cancer therapeutics market as these inks usually produce less volatile organic compounds and hazardous air pollutants.Also, the commercial printing segment is anticipated to expand at a significant pace due to the increase in the preference of pet cancer therapeutics in commercial printing such as architectural designs, textiles, fine arts, desktop publishing, advertising, and other applications.
The North America region is expected to dominate the global pet cancer therapeutics market owing to the huge presence of key players in the U.S and the existence of various pet cancer medicines and rise in healthcare spending on pets.Also, the North America region is expected to grow at a moderate pace owing to the rise in consumption for mast cell cancer applications.These factors expected to drive the pet cancer therapeutics market in the North America region.
The major players associated with the pet cancer therapeutics market are Aratana Therapeutics, Vetivax, Regeneus, Zoetis, AB Science, Merial, and VetDC, etc. There is a moderate level of competition seen among the manufacturers as they have targeted different pet cancers with their unique product offering.Moreover, the key players in the global pet cancer therapeutics market are also focusing mainly on forming strategic partnerships with other established players in order to expand their business geographically in order to gain significant market share.
Market By Medicine Type
Market By Species
Market By Cancer Type
Market By Geography